# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Chemomab had previously announced on November 6, 2023, that it was notified by Nasdaq that it was not in compliance with the mi...
Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing saf...
Pursuant to the terms of the securities purchase agreement, the Company is selling to certain investors (i) 4,188,867 Americ...
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12018074